34 results about "Flavanonol" patented technology

The invention discloses a method for simultaneously preparing total flavone extract and total alkaloid extract of Radix sophorae flavescentis. Total flavone extract mainly comprises flavanones (flavanonols) such as norkurarinone, kurarinone, and isokurarinon and other flaconoids such as trifolirhizin, xanthohumol, and kuraridin. Total alkaloid extract mainly comprises matrine n-oxide, N-oxysophocarpine, matrine, sophocarpine, sophoridine, and sophoramine. Total flavone extract and total alkaloid extract can be extracted through one or more of methods of solvent-extraction, solvent extraction, macroporous adsorbent resin, extraction by supercritical fluid, column chromatography, and liquid-liquid countercurrent distribution chromatography. Flavonoid content in total flavone extract is 5-100wt%, wherein the content of norkurarinone, xanthohumol, kuraridin, and trifolirhizin occupies 1-100wt%.Alkaloid content in total alkaloid extract is 5-100wt%, wherein the content of matrine n-oxide, N-oxysophocarpine, matrine and sophocarpine occupies 5-100wt%.

The invention relates to a novel 5, 6, 7- tri-oxygen Dihydroflavonol, shown in formula (1), the preparation method and its application. The compound can be used to prepare drug combination that can prevent hepatitis b, protect liver, treat fungal infection, prevent diseases that generates free radical during disease change including inflammation, autoimmune diseases, radiotherapy sequela, tumor, myocardial ischemia, cardiac hypertrophy, aging, allergic reaction and atherosclerosis. There are various preparations for said drug combination.

A botanical antioxidant composition includes a botanical antioxidant extract blend including a first antioxidant botanical extract including at least one hydroxycinnamic acid, and at least one additional antioxidant botanical extracts including at least one antioxidant selected from the group consisting of vitamins, stilbenoids, curcumininoids, tannins, flavones, flavonols, flavan-3-ols, flavanones, anthocyanidins, anthocyanins, isoflavones, flavanonols, proanthocyanidins, dihydroxybenzoic acids, and pyridine alkaloids.

An emulsified cosmetic for eyebrows or eyelashes with reduced irritation to the eyes and capable of suppressing the occurrence of dryness of the skin around the roots of the eyebrows or eyelashes and of retaining elasticity of the skin is provided. The emulsified cosmetic contains 0.01 to 1% by mass of a flavanonol derivative represented by the following formula (1) (wherein R 1 and R 2 are each independently a hydrogen atom or a methyl group) and 5 to 65% by mass of a volatile oil selected from volatile hydrocarbon oils and volatile silicone oils. The flavanonol derivative is dissolved in the volatile oil.

The invention discloses a method for increasing proanthocyanidin content in escherichia coli by cotransformation of brassica juncea gene BAN and DFR. According to the invention, an anthocyanidin reductase BAN gene and a 4-flavanonol reductase DFR gene are cloned from cDNA of brassica juncea purple-leaf mustard seed coat; a prokaryotic expression vector pET-BAN-DFR containing the BAN and DFR genesis constructed; and the BAN and the DFR genes are introduced into DH5alpha escherichia coli simultaneously. The transformed strain is cultured in an LB liquid medium at 25-37 DEG C at 150-250 rpm for6-12 hours, then cultured under shaking in an LB liquid medium containing black soybean seed coat extracts (0.5-1.0 g / L) at 25-37 DEG C at 150-250 rpm for 36-54 hours; the strain is collected by centrifugation; and the proanthocyanidin content in escherichia coli is determined by a DMACA-HCl method. The transgenic escherichia coli obtained in the invention has significantly increased proanthocyanidin content, and the maximum content can be 19.8 times higher than that of a non-transformed control strain.

The invention relates to application of lignin flavanonol in preparation of antiviral drugs, particularly, the invention relates to a chemical compound as formula (I), (+-)-2-[2,3-dihydro-2-(3,5-dimethoxy-4-hydroxy phenyl)-3-hydroxymethyl-1,4-benzodioxane-5]-2,3-dihydro-3,5,7-trihydroxy-4H-1-benzopyrone-4-ketone, or use of its medicinal salt used for preparing drugs for repressing herpes simplex virus and / or influenza virus. Pharmacological experiments in vitro shows that the chemical compound (I) can not only repress growth of herpes simplex virus HSV-1, HSV-2 obviously, and repress influenza virus effectively. And so it is expected to be develpoed as anti-infective agents for curing I / II type herpes simplex virus, or develpoed as viral influenza drugs infected by IV A virus.

The invention relates to a novel 5, 6, 7- tri-oxygen Dihydroflavonol, shown in formula (1), the preparation method and its application. The compound can be used to prepare drug combination that can prevent hepatitis b, protect liver, treat fungal infection, prevent diseases that generates free radical during disease change including inflammation, autoimmune diseases, radiotherapy sequela, tumor, myocardial ischemia, cardiac hypertrophy, aging, allergic reaction and atherosclerosis. There are various preparations for said drug combination.

The invention discloses a method for simultaneously preparing total flavone extract and total alkaloid extract of Radix sophorae flavescentis. Total flavone extract mainly comprises flavanones (flavanonols) such as norkurarinone, kurarinone, and isokurarinon and other flaconoids such as trifolirhizin, xanthohumol, and kuraridin. Total alkaloid extract mainly comprises matrine n-oxide, N-oxysophocarpine, matrine, sophocarpine, sophoridine, and sophoramine. Total flavone extract and total alkaloid extract can be extracted through one or more of methods of solvent-extraction, solvent extraction,macroporous adsorbent resin, extraction by supercritical fluid, column chromatography, and liquid-liquid countercurrent distribution chromatography. Flavonoid content in total flavone extract is 5-100wt%, wherein the content of norkurarinone, xanthohumol, kuraridin, and trifolirhizin occupies 1-100wt%.Alkaloid content in total alkaloid extract is 5-100wt%, wherein the content of matrine n-oxide, N-oxysophocarpine, matrine and sophocarpine occupies 5-100wt%.

The invention discloses a deeply-cold quick-frozen treatment agent for solenocera crassicornis. The deeply-cold quick-frozen treatment agent is prepared from the following components in percentage by mass: 5-10% of glycerine, 1-3% of carnosol, 0.01-0.03% of transglutaminase, 1-3% of cysteine, 0.5-1% of betaine, 0.1-0.3% of arbutin, 0.1-0.3% of dihydroflavonol, 0.1-0.3% of cuminic acid, 0.5-1% of konjac glucomannan and the balance of water. The deeply-cold quick-frozen treatment agent for solenocera crassicornis is reasonable and scientific in formula, is good in fresh-keeping and color-protection effect, can prevent the situation that solenocera crassicornis heads come off from solenocera crassicornis bodies, and can effectively restrain nigrities. The invention further discloses an application of the deeply-cold quick-frozen treatment agent for solenocera crassicornis in deeply-cold quick-frozen solenocera crassicornis. The solenocera crassicornis is soaked in the deeply-cold quick-frozen treatment agent for at least 10min, then draining is performed, and liquid nitrogen deeply-cold quick-frozen treatment is performed, so that the method is simple in steps and high in maneuverability.

The invention relates to application of B-ring ethyoxyl flavanonol in preparing medicaments for treating hepatitis B viruses, in particular to application of a compound as shown in a formula (1) or a medicinal salt thereof in preparing medicaments for clearing away hepatitis B virus surface antigens (HBsAg) and hepatitis B e-antigen (HBeAg) and medicaments for inhibiting the duplication of hepatitis B virus desoxyribonucleic acid (HBV DNA). The compound or the medicinal salt thereof has extremely obvious activity on inhibiting the HBsAg and the HBeAg, and in the presence of a concentration of20 microgram / milliliter, the intensities for clearing away the HBsAg and the HBeAg of the compound or the medicinal salt thereof are respectively 99.8 percent and 48.5 percent and are 6.2 times and 2.7 times of that of alpha-interferon which is a positive control medicament. More importantly, in the presence of the concentration, the inhibition ratio of the compound or the medicinal salt thereof to the HBV DNA is 64.7 percent, and the activity is 1.7 times of that of the alpha-interferon. Accordingly, the flavone lignan or the medicinal salt thereof can be expected to be used for preparing non-nucleoside medicaments for treating infectious diseases of the hepatitis B viruses.

The invention relates to medicinal application of flavanonol lignan in preparing glycosidase inhibitors, in particular to application of B-ring dioxane flavanonol lignan or pharmaceutically acceptable salts thereof in preparation medicines for inhibiting alpha-glucosidase and preventing type 2 diabetes. The flavone lignan has extremely obvious activity of inhibiting the alpha-glucosidase and has the activity strength of inhibiting the alpha-glucosidase at the concentration of 40 micrograms / milliliter of 93 percent; and a half inhibitory concentration test shows that: the strength of the flavone lignan of inhibiting the alpha-glucosidase is 1.2 times that of a positive contrast medicine acarbose. A pharmacodynamic result shows that the flavone lignan or the pharmaceutically acceptable salts thereof can be expected to serve as the glycosidase inhibitors, particularly serve as medicines for preventing the type 2 diabetes.

The invention relates to application of flavanonol lignanoid in preparing an antiviral hepatitis B medicine, in particular to application of angle flavanolignan or pharmaceutically acceptable salts thereof in preparing a medicine which can be used for eliminating hepatitis B e antigen HBeAg, inhibiting HBV DNA replication and treating hepatitis B virus infection diseases. The flavanolignan has a certain HBeVg activity inhibition, the HBeAg elimination intensity of the flavanolignan is higher than that of a positive control first-line medicine as lamivudine in light concentration and is equivalent to that of alpha-interferon of 1000 unit / ml, and meanwhile, under the concentration of 20 microgram / ml, the flavanolignan displays an inhibition ratio which is larger than 45 percent for HBV DNA.The pharmacodynamics result indicates the application of the flavanolignan or the pharmaceutically acceptable salts thereof in preparing the medicine as expected for eliminating hepatitis B e antigen, inhibiting HBV DNA replication and treating hepatitis B virus infection diseases.

The invention relates to application of lignin flavanonol in preparation of antiviral drugs, particularly, the invention relates to a chemical compound as formula (I), (+-)-2-[2,3-dihydro-2-(3,5-dimethoxy-4-hydroxy phenyl)-3-hydroxymethyl-1,4-benzodioxane-5]-2,3-dihydro-3,5,7-trihydroxy-4H-1-benzopyrone-4-ketone, or use of its medicinal salt used for preparing drugs for repressing virus infectioncaused by herpes simplex virus HSV-1 and / or drugs for curing oral ulcer. The chemical compound is prepared by chemical synthesis, pharmacological experiments shows that, the chemical compound has powerful inhibitory action to the herpes simplex virus HSV-1, and the half inhibitory concentration value IC[50] is 39.41 mg / mL.

The invention relates to a gene sequence of flavanonol 4-reductase synthesized by anthocyanins of an eggplant, belonging to the technical field of biology. The gene sequence has a nucleotide sequence as shown in 1st-1149th places of nucleotide in SEQ ID NO. 1; and another sequence has a nucleotide sequence as shown in 1st-1149th places of the nucleotide in SEQ ID NO. 3. In the invention, an eggplant variety has significant characteristics on the aspects of high anthocyanins, water stress resistance, uvioresistant protection, and the like, can be obtained; substances, receptors, inhibitors or antagonists, and the like relatively interacted with the flavanonol 4-reductase can be screened through various conventional screening methods by utilizing a flavanonol 4-reductase gene of the eggplant.

The present invention refers to the technical field of flavone component extraction, and provides an extraction separation method of a flavone component based on amination graphene. The flavone components comprise flavones, flavanols, isoflavones, flavanones, flavanonols, flavanones, anthocyanidins, chalcones, and chromones etc. The extraction separation method is adsorption extraction, and amination graphene is taken as a medium of adsorption extraction. The extraction separation method of the flavone components based on amination graphene is superior in separation speed and product purity, low cost and convenient operation.

The invention relates to a method for extracting 3,4',7-trihydroxy flavanonol and fustin with the antioxidant activity from varnish tree wood meal, and belongs to the field of development and application of plant extracts and chemistry of natural products. The varnish tree wood meal is used as a raw material, extraction, silica gel column chromatography and middle-lowerpressure chromatography are performed to obtain the 95% or above 3,4',7-trihydroxy flavanonol and fustin. The ingredients with the efficient antioxidant activity are obtained from a varnish tree, and the removal rate of DPPH, ABTS and hydroxyl radicals is higher than 95% when the concentration is 50 mg / L or above. The preparation process is rapid and simple, the extracted 3,4',7-trihydroxy flavanonol and fustin are good sources for developing a potential natural antioxidant, and the good commercial prospect is achieved.

The present invention has an object to provide an agent for strengthening calcium-containing tissues, which can be safely applied; and its use: The present invention solves the object by providing an agent for strengthening calcium-containing tissues, which comprises one or more flavones, flavonols, flavanones, flavanonols, anthocyanidins, flavanols, chalcones, and aurones.